Miragen Therapeutics Inc Share Price Nasdaq
Equities
US8266402036
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
11/06 | Sector Update: Health Care Stocks Mixed Premarket Tuesday | MT |
11/06 | Sector Update: Health Care | MT |
Sales 2024 * | 3L 2.92Cr | Sales 2025 * | 3L 2.54Cr | Capitalization | 94Cr 7.83TCr |
---|---|---|---|---|---|
Net income 2024 * | -23Cr -1.92TCr | Net income 2025 * | -27Cr -2.26TCr | EV / Sales 2024 * | 1,361 x |
Net cash position 2024 * | 46Cr 3.86TCr | Net cash position 2025 * | 63Cr 5.22TCr | EV / Sales 2025 * | 1,025 x |
P/E ratio 2024 * |
-3.96
x | P/E ratio 2025 * |
-3.68
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.26% |
Latest transcript on Miragen Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 30/23/30 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 01/23/01 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/23/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 03/18/03 |
Tomas Kiselak
CHM | Chairman | 37 | 28/20/28 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 30/23/30 |
1st Jan change | Capi. | |
---|---|---|
+25.46% | 4.66TCr | |
+45.38% | 4.17TCr | |
+0.27% | 4.12TCr | |
+33.52% | 3.24TCr | |
+20.93% | 2.82TCr | |
-6.35% | 2.81TCr | |
+49.21% | 1.45TCr | |
+47.47% | 1.37TCr | |
+3.16% | 1.22TCr |